Aidoc Funding, Investors & Competitors

Aidoc has raised $524M across 9 funding rounds, most recently a $150M Series E in April 2026.

See full Aidoc profile

Last Aidoc funding round

$150M

Series E · Apr 2026

Cumulative funding Aidoc raised

$524M

across 9 funding rounds

Key investors in Aidoc

  • General Catalyst
  • TCV
  • Square Peg Capital
  • TLV Partners
  • Magma Venture Partners
  • Emerge Ventures
  • NVentures
  • Synetro Group

Aidoc Overview

About Aidoc

Aidoc is a provider of the aiOS clinical AI platform for medical imaging analysis. Headquartered in Tel Aviv, it processes CT scans and X-rays to detect urgent conditions like pulmonary embolism and stroke. Aidoc integrates with radiology workflows, PACS systems, and EHRs to prioritize cases and notify teams in real time across cardiology and vascular specialties.


Founded

2016

HQ

IsraelTel Aviv

Website

aidoc.com

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Aidoc Funding History

Aidoc has raised a total of $524M across 9 funding rounds.

Aidoc's first fundraising round was a $4M seed round in October 2016. The most recent completed round was a $150M Series E in April 2026.

Aidoc funding rounds

Aidoc funding rounds
DateStageInvestorsRaisedDeal Summary
Apr 2026Series EGoldman Sachs Asset Management (lead); General Catalyst; SoftBank Group; NVentures; Square Peg; TCV; TLV Partners$150MAidoc, a clinical AI company founded in Israel, raised $150 million in Series E funding led by Growth Equity at Goldman Sachs Alternatives in April 2026. General Catalyst, SoftBank Vision Fund 2, and NVentures (NVIDIA's venture capital arm) participated in the round. The funding brings Aidoc's total capital raised to over $500 million, with the previous $150 million growth round occurring approximately nine months earlier and also led by General Catalyst alongside Square Peg. The Series E capital will support expansion of Aidoc's clinical AI foundation model across additional medical indications, development of end-to-end AI capabilities spanning CT and X-ray imaging with automated draft report generation, and global deployment of its aiOS platform. The company received regulatory clearance for its AI model in January 2026. Aidoc operates across 2,000+ hospitals worldwide and counts major U.S. health systems including Mercy and Hartford HealthCare among its investors, alongside Amazon Web Services. The company is reportedly considering an IPO following this funding round.
Jul 2025Undisclosed stageGeneral Catalyst (lead); Square Peg Capital (lead); NVentures; Hartford HealthCare; Mercy; WellSpan Health; Sutter Health$110MAidoc is a clinical AI platform founded in 2016 that provides FDA-cleared AI-powered diagnostic tools across radiology, cardiology, neurovascular, vascular and plans to enter oncology. The company developed CARE, a clinical-grade foundation model designed to assist physicians in clinical decision-making by compressing what would be decades of product roadmap into years. Aidoc currently supports care for over 45 million patients annually across 150+ health systems, including Mount Sinai Health System, Yale New Haven Health System, Northwell Health, University of Miami Health System and Temple Health, with plans to reach 100 million patients within three years. In July 2025, Aidoc closed a $150 million Series E financing round led by General Catalyst and Square Peg Capital with participation from NVentures (Nvidia's venture capital arm) and four major U.S. health systems as strategic investors: Hartford HealthCare, Mercy, Sutter Health, and WellSpan Health. The round included a $40 million revolving credit facility, bringing total funding to $370 million. The company has secured 18 FDA-cleared algorithms in radiology and two CARE-powered solutions have received FDA clearance for rib fracture and aortic dissection detection. Aidoc plans to invest more than $150 million over the coming years through strategic partnerships with Nvidia and Amazon Web Services to bring CARE to market, leveraging high-performance computing and AI development platforms while expanding its aiOS enterprise platform that enables health systems to deploy and govern multiple AI solutions.
Nov 2023Undisclosed stage-$30MAidoc is a leading provider of healthcare AI solutions, specializing in imaging AI platforms that assist radiologists and clinicians in triaging conditions, managing workflows, and improving patient outcomes across specialties like radiology, cardiology, and neurovascular care. In November 2023, Aidoc secured $30 million in funding, as noted in multiple reports, to develop a comprehensive AI imaging model powered by imaging data aimed at enhancing diagnostic precision and early detection. This round fits into the company's broader fundraising trajectory, bringing total funding closer to subsequent totals reported as $370 million by early 2025 after larger raises. The investment supported expansion amid post-pandemic challenges like physician shortages and rising costs, positioning Aidoc's AI Care Platform to integrate deeply into hospital workflows. The 2023 funding came after Aidoc's prominent $110 million Series D round announced earlier, co-led by TCV and Alpha Intelligence Capital, which brought total funding to $250 million at that time and focused on scaling the AI Care Platform for cross-specialty care teams. By late 2023 and into 2024-2025, Aidoc raised additional significant capital, including a $150 million round led by General Catalyst and Square Peg with participation from NVentures (NVIDIA) and health systems like Hartford HealthCare and Sutter Health, plus a $40 million revolving credit facility, pushing cumulative funding to $370 million. These funds accelerated development of CARE, a clinical-grade foundation model with FDA-cleared solutions, and aiOS, an operating system for deploying and governing multiple AI models at scale. Aidoc supports over 150 health systems and 45 million patients annually as of 2025 reports, with growth plans to 100 million patients, partnering with institutions like Mount Sinai, Yale New Haven, and Northwell Health. The company leverages strategic ties with NVIDIA and AWS for high-performance AI development, enabling 20x faster application creation covering 90% of clinically relevant diseases including oncology and cardiovascular conditions.
Jun 2022Series DAlpha Intelligence Capital (lead); TCV (lead); Synetro Group; CDIB Capital$110M-
Jul 2021Series CGeneral Catalyst (lead); TCV; Synetro Group$66MAidoc is an artificial intelligence company developing triage and analysis software for medical imaging, focusing on flagging acute anomalies in real time to expedite patient treatment and improve care quality. The company announced a $66 million Series C funding round on July 13, 2021, led by General Catalyst with participation from Synetro Group and TCV, bringing total funding to $140 million. This followed prior raises totaling about $67 million and was driven by surging demand for Aidoc's AI solutions, including the largest clinical deployment through its partnership with Radiology Partners. Aidoc had expanded its product lines, doubled FDA clearances, and quadrupled its customer base leading into the round. It reported almost 600 partnerships with hospitals and clinics worldwide, such as Yale New Haven Medical Center, Cedars-Sinai, and Sheba Medical Center, and projected use in 10 percent of US hospitals within two years. The CEO noted a seven-fold increase in contracted annual recurring revenue from Q1 2020 to Q1 2021 despite pandemic-related slowdowns, with the platform having analyzed over 8 million cases by mid-2021. Post-round developments included further funding like a $110 million Series D in June 2022 and later rounds totaling over $418 million by 2025, alongside growth to support over 45 million patients annually across 150+ health systems and more than 20 FDA clearances.
Sep 2020Series BSquare Peg Capital (lead)$20MAidoc is an Israeli-founded AI medical imaging startup established in 2016 by Guy Reiner, Elad Walach, and Michael Braginsky, all graduates of the elite Israeli military Talpiot program. The company develops full-body AI software using deep learning to analyze medical scans, detect critical anomalies such as strokes, spine fractures, pulmonary embolisms, brain hemorrhages, and COVID-19 findings, with six FDA-cleared products at the time. This technology assists radiologists in prioritizing patients and improving care efficiency. On September 16, 2020, Aidoc raised an additional $20 million in a Series B extension led by Square Peg Capital, bringing the total round to $47 million and cumulative funding to $60 million. Square Peg partner Dan Krasnostein highlighted Aidoc's leadership in radiology AI, product advancements, and customer growth since their initial investment. CEO Elad Walach stated the funds would expand the product portfolio and global practices. Later rounds included a $66 million Series C in 2021, $110 million Series D in 2022 co-led by TCV and Alpha Intelligence Capital (total funding to $250 million), and a $150 million round in 2024 led by General Catalyst and Square Peg with NVentures and health systems, plus a $40 million credit facility (total to $370 million). These supported expansions into oncology, cardiology, aiOS platform, and CARE foundation model, with two CARE-powered FDA clearances and rollouts at systems like Advocate Health. Aidoc supports over 45 million patients annually across 150+ health systems as of 2024, aiming for 100 million in three years, partnering with Mount Sinai, Yale New Haven, Northwell, University of Miami, and Temple Health. Investments with NVIDIA and AWS exceed $150 million for CARE development.
Apr 2019Series BSquare Peg Capital (lead); Magma Venture Partners; Emerge Ventures; TLV Partners$27MAidoc is a Tel Aviv-based AI company specializing in medical imaging analysis, using AI to analyze medical scans and assist physicians in detecting conditions like brain hemorrhages, pulmonary embolisms, and strokes. Founded in 2016 by Elad Walach, Michael Braginsky, and Guy Reiner, all IDF Talpiot program graduates, the company develops FDA-cleared algorithms integrated into hospital workflows. By April 2019, Aidoc had grown its team from 5 to 60 employees, secured FDA clearances and European CE marks, participated in clinical studies, and was deployed in 100 sites, aiming for 500 hospitals within two years. On April 17, 2019, Aidoc raised $27 million in a Series B funding round led by Square Peg Capital, with participation from existing investors Emerge Ventures, Magma Venture Partners, and TLV Partners. This brought the company's total funding to $40 million at the time. Aidoc collaborated with the American College of Radiology's DSI to monitor the real-world performance of its deployed solutions, emphasizing clinical impact for broader AI adoption in medicine. The company focused on rapid scaling to deliver value to patients across more hospitals. Subsequent rounds included $47 million in 2020, $66 million Series C in 2021, $110 million Series D in 2022, and a $150 million round in 2025 led by General Catalyst and Square Peg, plus a $40 million credit facility, bringing total funding to $370 million then and $418.6 million overall per some trackers, with deployments in 150+ health systems supporting 45 million patients annually. Later developments highlight Aidoc's expansion into foundation models like CARE for faster development of FDA-cleared applications in areas like oncology and cardiology, with partnerships including NVIDIA, AWS, and major U.S. health systems such as Sutter Health and Mount Sinai.
Apr 2017Series ATLV Partners (lead); Magma Venture Partners; Emerge Ventures$7MAidoc Medical, an Israeli artificial intelligence startup focused on medical imaging analysis, closed a $7 million funding round on April 26, 2017, led by TLV Partners with participation from existing investors Magma Ventures and Emerge Ventures. This brought the company's total funding raised to $10.5 million at that point. The funds were allocated to expand its core R&D team, customer success, and marketing efforts in the US and Israel. Aidoc develops AI technology to analyze diagnostic images such as CT and MRI scans, aiming to assist radiologists handling high volumes of patients. Founded by CEO Elad Walach, CTO Michael Braginsky, and VP R&D Guy Reiner, the company targets inefficiencies in radiology workflows. TLV Partners highlighted advancements in AI, open-sourcing, reduced compute costs, and data availability as enablers for innovation in medical imaging.
Oct 2016SeedMagma Venture Partners (lead); Emerge Ventures$4M-

Who has invested in Aidoc?

17 investors have backed Aidoc across its funding rounds, including General Catalyst, TCV, Square Peg Capital, TLV Partners, Magma Venture Partners and Emerge Ventures.

Lead investors include Goldman Sachs Asset Management, General Catalyst, Square Peg Capital, Alpha Intelligence Capital, TCV and 2 other investors.


Aidoc Investors

Investors in Aidoc by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA3LeadJul 2021
Magma Venture PartnersIsraelTel Aviv3LeadOct 2016
Emerge VenturesIsraelTel Aviv3ParticipantOct 2016
TCVUnited StatesSan Francisco, CA3LeadJul 2021
Square Peg CapitalAustraliaSydney3LeadApr 2019
TLV PartnersIsraelTel Aviv3LeadApr 2017
NVenturesUnited StatesSan Jose, CA2ParticipantJul 2025
Synetro GroupUnited StatesChicago, IL2ParticipantJul 2021
SoftBank GroupJapanTokyo1ParticipantApr 2026
Hartford HealthCareUnited StatesHartford, CT1ParticipantJul 2025
Square PegUnited KingdomBetchworth1ParticipantApr 2026
MercyUnited StatesSaint Louis, MO1ParticipantJul 2025
WellSpan HealthUnited StatesYork, PA1ParticipantJul 2025

This data is available for Pro users. Sign up to see all 17 Aidoc investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Aidoc Competitors

Aidoc competitors include listed companies like GE HealthCare, United Imaging and Pro Medicus, and private ones like ConcertAI, United Imaging Intelligence and Hippocratic AI.

Public and private companies comparable to Aidoc
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
GE HealthCareUnited StatesUnited StatesPublicly listed$21B$3.7B$29B1.8x
United ImagingChinaChinaPublicly listed$2.1B$367M$12B4.8x
ConcertAIUnited StatesUnited StatesPrivate$200M-$1.9B9.5x
United Imaging IntelligenceChinaShanghaiPrivate--$1.4B-
Pro MedicusAustraliaAustraliaPublicly listed$186M$147M$13B62.7x
Hippocratic AIUnited StatesSan Francisco, CAPrivate--$3.5B-

Aidoc Public Comps

Aidoc is still privately-owned, but its public comps include CrowdStrike, SAP, Salesforce, ServiceNow, Adobe, Datadog, Moody's, Natera, Workday and IQVIA.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x
SAP$42B$13B5.8x5.4x18.4x17.1x
Salesforce$42B$13B5.5x5.2x17.8x12.2x
ServiceNow$13B$2.6B11.1x9.6x57.2x25.0x
Adobe$24B$9.3B4.3x3.9x10.9x8.2x
Datadog$3.4B($588K)23.6x19.4x(137813.0x)77.6x
Moody's$7.7B$3.8B11.2x10.6x22.5x20.1x
Natera$2.3B($266M)22.5x19.0x(195.0x)(261.5x)

This data is available for Pro users. Sign up to see all Aidoc competitors and their valuation data.

Start Free Trial

Common questions about Aidoc

When was Aidoc founded?Aidoc was founded in 2016.
Where is Aidoc headquartered?Aidoc is headquartered in Tel Aviv, Israel.
Is Aidoc publicly listed?No, Aidoc is a private, VC-backed company.
How much funding has Aidoc raised?Aidoc has raised $524M across 9 funding rounds.
What was Aidoc's last funding round?Aidoc's last funding round was a $150M Series E in April 2026, led by Goldman Sachs Asset Management.
Who are Aidoc's investors?Aidoc's investors include General Catalyst, Magma Venture Partners, Emerge Ventures, TCV, Square Peg Capital, TLV Partners, NVentures, Synetro Group, SoftBank Group, Hartford HealthCare and 7 others.
Which companies are comparable to Aidoc?Companies comparable to Aidoc include GE HealthCare, United Imaging, ConcertAI, United Imaging Intelligence, Pro Medicus and Hippocratic AI.

See companies similar to Aidoc

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial